Stock Ratings / Health Care / LFCR / news

ELDN (49) EVMN (43) VNDA (37) CAMP (34) ⌘ Pro Terminal →

Why LFCR Stock advanced +0.15% Today — RQD Quant Desk Flash

$6.52 +0.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Lifecore Biomedical Inc. (LFCR) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $246.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFCR)Realized 20D OHLCV Swing Band: ±2%

AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why LFCR Stock advanced +0.15% Today — RQD Quant Desk Flash

Lifecore Biomedical Inc. (LFCR) advanced +0.15% to $6.52, trading at 54% of its 52-week range ($3.63 – $8.98). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

▸Technical Tape: Trading at 54% of its 52-week range ($3.63 – $8.98) with RSI-14 at 65.4 (BULLISH MOMENTUM).
▸Volatility Profile: Historical 20-day realized swing band of ±2% around $6.52 (no active unusual options sweep snapshot on file).
▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $6.9M annual free cash flow.

Live LFCR Headlines & Catalysts

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LFCR)

✓Walkthrough of LFCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LFCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +28.60%📐 HORIZONTAL RANGE

2026-10-30O $6.48H $6.52L $6.32C $6.52VOL 1.02M

RES: $7.29SUP: $3.90SMA50: $5.42SMA200: $5.51

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LFCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LFCR Butterfly Map → + Track LFCR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LFCR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LFCR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LFCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFCR)

Health Care Rank #336 of 1016 ⚔️ ELDN vs LFCR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LFCR vs. ELDN, EVMN, VNDA, CAMP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lifecore Biomedical Inc. (LFCR) ranks #336 by composite RQD confidence (51/100, grade D) and #550 by equity capitalization ($246.8M). Within this direct 5-issuer industry benchmark cohort, LFCR leads on earnings valuation at N/A trailing P/E, while ELDN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LFCR ACTIVE Lifecore Biomedical Inc.	D	51/100	—	—	—	+0.15%	$246.8M	Benchmark Subject
ELDN Eledon Pharmaceuticals Inc.	D	49/100	—	—	-35.0%	+10.15%	$247.0M	/eldn-vs-lfcr →
EVMN Evommune Inc.	D-	43/100	—	—	-35.0%	+7.92%	$247.1M	/evmn-vs-lfcr →
VNDA Vanda Pharmaceuticals Inc.	D-	37/100	—	—	-35.0%	+1.25%	$244.9M	/vnda-vs-lfcr →
CAMP CAMP4 Therapeutics Corporation	E	34/100	—	—	-35.0%	+6.85%	$244.7M	/camp-vs-lfcr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001005286

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lifecore Biomedical Inc. (LFCR) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $128.9M ) , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LFCR closed FY2025 with $232.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$232.2M	—
FY2024 (FY)	2025-05-25	$128.9M	-$38.7M	-$206.0K	-$13.6M	$255.4M	$110.5M
FY2023 (FY)	2024-05-26	$0	$12.0M	$257.0K	$257.0K	—	—

3. LFCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LFCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lifecore Biomedical Inc. (NASDAQ: LFCR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $6.52 (+0.15% 1D, market cap $246.8M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LFCR ranks #336 in composite RQD confidence.

How does LFCR compare to ELDN and EVMN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFCR carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ELDN (Eledon Pharmaceuticals Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $247.0M) and EVMN (Evommune Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $247.1M). Among the 5-stock peer group, LFCR leads on earnings multiple (N/A) while ELDN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LFCR?

Per LFCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001005286), Lifecore Biomedical Inc. generated $0 in revenue (-100.0% YoY), $0 in net income, and $0 in free cash flow against $232.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LFCR trading relative to its 50-day, 200-day, and 52-week technical levels?

LFCR last traded at $6.52 (+0.15% on volume of 240,912 shares), positioning the stock +20.30% above its 50-day simple moving average ($5.42) and +18.33% above its 200-day simple moving average ($5.51). Across its 52-week range of $3.63 to $8.98, LFCR sits at the 54.0% percentile with a 14-day RSI of 65.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±2.0% ($6.39 to $6.65).

LFCR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Why is LFCR stock moving today?

Why LFCR Stock advanced +0.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

Direct Sub-Reports: LFCR RQD Cockpit LFCR 12M Forecast LFCR Earnings & Move LFCR Dividends & DRIP LFCR Insiders & 13F LFCR Whale Options LFCR Profit Sankey LFCR News & Why